Home » Stocks » XENE

Xenon Pharmaceuticals Inc. (XENE)

Stock Price: $19.92 USD 0.15 (0.76%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 689.33M
Revenue (ttm) 32.17M
Net Income (ttm) -28.01M
Shares Out 34.54M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $19.92
Previous Close $19.77
Change ($) 0.15
Change (%) 0.76%
Day's Open 20.09
Day's Range 18.37 - 20.36
Day's Volume 191,599
52-Week Range 7.00 - 21.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for ...

Benzinga - 3 days ago

Shares of Xenon Pharmaceuticals (NASDAQ:XENE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 17.07% over the past year ...

GlobeNewsWire - 4 days ago

XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in  Third Quarter of 2021

GlobeNewsWire - 1 week ago

Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Con...

GlobeNewsWire - 1 week ago

Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia

GlobeNewsWire - 2 months ago

Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy (CAE) Early, Promising Data from Physician-Led ...

GlobeNewsWire - 3 months ago

BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xeno...

Seeking Alpha - 3 months ago

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -66.67% and -36.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...

Seeking Alpha - 4 months ago

Shares have risen by 15% since my March recommendation, but EV of around $180 million appears cheap contrasted to multiple opportunities in epilepsy that they are pursuing. I provide a recap o...

GlobeNewsWire - 4 months ago

BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third...

GlobeNewsWire - 4 months ago

Positive Opinion Received Supporting Orphan Medicinal Product Designation in Europe for XEN496 for the Treatment of KCNQ2-DEE Positive Opinion Received Supporting Orphan Medicinal Product Desi...

GlobeNewsWire - 4 months ago

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DE...

GlobeNewsWire - 6 months ago

BURNABY, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced today the appointment of Dr. C...

Seeking Alpha - 6 months ago

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 100.00% and 102.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 6 months ago

XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Anticipated in 2020

GlobeNewsWire - 7 months ago

BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its sec...

Business Wire - 7 months ago

BELLEVUE, Wash.--(BUSINESS WIRE)--Xenon arc Unveils Groundbreaking Voice of Customer Study Results Focused on Small-to-Mid Sized Business Customers

Business Wire - 7 months ago

LONDON--(BUSINESS WIRE)-- #GlobalXenonFlashLampMarket--The Global Xenon Flash Lamp Market will grow by $ 46.40 mn during 2020-2024

Seeking Alpha - 9 months ago

Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 29.03% and -5.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 9 months ago

Progress Reported in Both Proprietary and Partnered Neurology Clinical Programs 

Seeking Alpha - 10 months ago

Xenon Remains Well-Positioned And Well-Funded Despite COVID-19 Related Setbacks

GlobeNewsWire - 11 months ago

BURNABY, British Columbia, March 31, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update in the c...

GlobeNewsWire - 11 months ago

BURNABY, British Columbia, March 26, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants t...

Seeking Alpha - 11 months ago

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

If you can handle the uncertainty, these small-cap stocks can make you very wealthy.

Other stocks mentioned: EDIT, RHHBY
GlobeNewsWire - 1 year ago

BURNABY, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the underwriters of it...

The Motley Fool - 1 year ago

These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.

Other stocks mentioned: AUPH, ZYME
Seeking Alpha - 1 year ago

Xenon Pharmaceuticals Is Poised For Significant Progress In 2020

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for February 4th

Other stocks mentioned: MLNX, RLI
GlobeNewsWire - 1 year ago

BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previous...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for January 24th

Other stocks mentioned: ACMR, MS, SIG
Zacks Investment Research - 1 year ago

Does Xenon Pharmaceuticals (XENE) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 1 year ago

BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwri...

GlobeNewsWire - 1 year ago

BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an un...

GlobeNewsWire - 1 year ago

Xenon ’ s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials  Anticipated to be Underway in 2020

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Xenon Pharmaceuticals.

Seeking Alpha - 1 year ago

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Xenon Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

BURNABY, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, X...

GlobeNewsWire - 1 year ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seeking Alpha - 1 year ago

Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Xenon Pharmaceuticals (XENE) CEO Simon Pimstone on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Shares of Xenon Pharmaceuticals rose by as much as 150% a couple quarters after my May 2018 Reader Inquiry piece was published (thanks to ROTY member XavierD for bringing it to my attention).

About XENE

Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical... [Read more...]

Industry
Biotechnology
IPO Date
Nov 5, 2014
CEO
Simon Pimstone
Employees
100
Stock Exchange
NASDAQ
Ticker Symbol
XENE
Full Company Profile

Financial Performance

In 2020, XENE's revenue was $32.17 million, an increase of 371.02% compared to the previous year's $6.83 million. Losses were -$28.84 million, -30.67% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price forecast is 25.29, which is an increase of 26.96% from the latest price.

Price Target
$25.29
(26.96% upside)
Analyst Consensus: Strong Buy